Articles by Tomas Philipson, PhD
Tomas Philipson, PhD, says historical reform efforts in the United States have raised doubts as to whether or not the implementation of the Affordable Care Act will slow health spending growth. Dr Philipson also suggests that concepts of value-based insurance design must be considered differently when managing a chronic condition like diabetes.
The Option Value of Innovative Treatments in the Context of Chronic Myeloid Leukemia
ByYuri Sanchez, PhD,John R. Penrod, PhD,Xiaoli Lily Qiu, PhD,John Romley, PhD,Julia Thornton Snider, PhD,Tomas Philipson, PhD Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.
